Company* |
Company* |
Type/Product Area | Terms/Details (Date) |
Adventrx |
Hyaluron Contract Manufacturing* |
Agreement to manufacture ANX-514 for preclinical and clinical studies |
Adventrx intends to seek FDA guidance regarding a 505 b)(2) regulatory path for the product and will start a marketing- enabling trial later this year(4/5) |
Adventrx |
Pharmatek Laboratories Inc.* |
Manufacturing agreement for Adventrx's ANX-201 (Thiovir) capsules for clinical studies |
Phase I/II combination trials in HIV patients are expected to begin in the third quarter (3/20) |
Aldagen Inc.* |
StemCell Technologies Inc.* |
Worldwide distribution agreement under which StemCell will distribute Aldagen's Aldecount product |
Terms of the deal were not disclosed (3/2) |
Alteon Inc. |
OXIS International Inc. (OTC BB:OXIS) |
Expanded license agreement under which Alteon picks up exclusive worldwide rights to ALT- 074 and all related organoselenium compounds in OXIS' library for development and commercialization in all indications |
Alteon agreed to invest at least $7.5M in OXIS over a three-year period; the deal also includes milestone payments to OXIS, plus any sublicensing fees or royalties; Alteon also will make an equity investment for net proceeds of $500,000 (4/9) |
Antisoma plc |
Microtest* |
Agreement to begin the aseptic manufacturing of the cancer drug AS1411 |
Microtest will handle formulation and aseptic fill/finish of AS1411 material supply for upcoming Phase II trials and will be responsible for stability testing of the compound (3/26) |
Celogos* |
Stem Cell Sciences KK (joint venture between Stem Cell Sciences Ltd., Australia, LSE:STEM;and Sosei Co. Ltd., Japan) |
License agreement covering technologies for myoblast cell implantation to treat stress urinary incontinence |
Celogos has granted SCSKK exclusive rights to commercialize in Japan therapeutic products related to myoblast implantation (2/21)** |
Cepheid Inc. |
VWR International* |
Agreement to distribute Cepheid Industrial life science products in the U.S. |
The nonexclusive deal expands Cepheid's industrial market reach by extending its domestic sales channel; financial terms were not disclosed (4/17) |
Clinical Data |
Epigenomics AG (Germany; FSE:ECX) |
Agreement for Clinical Data's Cogenics service division to offer the DNA methylation services of Epigenomics |
Epigenomics also will promote Cogenics' pharmacogenomics and molecular biology services to its DNA methylation biomarker development partners and customers (4/12) |
Cobra Biomanufacturing |
Pharmexa AB (Denmark; CSE:PHARMX) |
Manufacturing agreement for Phase I supplies of a protein vaccine PX107 for treating bone disorders |
The program will include cell banking, process development and GMP manufacture (2/7)**# |
Competitive |
Quest |
Expanded license agreement concerning the production of enterovirus assay kits |
Competitive Technologies out-licensed the kits for the University of Colorado (4/13) |
Crucell NV |
Talecris Biotherapeutics GmBH* |
Long-term distribution deal under which Crucell will serve as the exclusive distributor of Talecris' Prolastin (alpha-1 proteinase inhibitor) in nine Western European countries |
The deal is the first full use of Crucell's new pan- uropean marketing and sales organization (4/3) |
Cytyc Corp. |
Quest Diagnostics Inc. (NYSE:DGX) |
Agreement for Cytyc to supply the ThinPrep Pap Test to Quest |
The new agreement will run through the end of 2010; Quest also agreed to evaluate the ThinPrep Imaging System at certain laboratory sites (3/28) |
Genta Inc. |
IDIS World Medicines* (UK) |
Distribution agreement for two of Genta's oncology products: Ganite and Genasense |
The agreement covers all territories except the U.S. (3/7) |
GTC |
PharmAthene Inc.* |
Agreement under which GTC will provide process development and clinical supply manufacturing services for PharmAthene's Protexia program |
Protexia is a recombinant form of human butyrylcholinesterase produced in the milk of transgenic goats to treat victims of a chemical nerve agent attack (3/5) |
Human Genome |
MedImmune Inc. (MEDI) |
MedImmune is leasing a portion of an HGS manufacturing facility in Rockville, Md. |
The pace will be used for development and manufacturing of clinical trial material for cell culture- based seasonal and pandemic influenza vaccine; terms of the deal were not disclosed (3/16) |
ProMetic |
Tecpar* (Brazil) |
Technology transfer and licensing agreement for Tecpar to manufacture a complex biopharmaceutical product for the Brazilian domestic market as well as all other South American countries |
The total transaction is valued at C$19M (US$16.41M); ProMetic will receive about C$9M for license, milestone and development payments, and C$10M will go to modify Tecpar's current facility (3/22) |
Senetek plc |
Valeant Pharmaceuticals North America Inc. (NYSE:VRX) |
Monetization agreement under which Senetek granted Valeant a paid-up license for Kinetin anti-aging active ingredient and Zeatin, a Kinetin analog |
Senetek assigned Valeant future royalties from other Kinetin licensees; in return, Senetek will receive a cash payment of $21M, forgiveness of a $6M prepaid royalty credit reimbursement obligation and a right to share in future royalties due to Valeant from other Kinetin licensees through 2011 (4/2) |
Shanghai |
Blue Blood Biotech Corp.* (Taiwan) |
Technical cooperation agreement for a development investigation into the mass production of recombinant NEFG protein |
Blue Blood will pay Shanghai $400,000 for the work; the drug is being developed to treat diabetes patients (4/16) |
Synco Bio |
Prosensa BV* (the Netherlands) |
Collaboration for the formulation and fill of RNA- based therapeutics for Duchenne's muscular dystrophy |
The agreement involves Prosensa's lead product, an RNA- based drug; terms call for SynCo to work with Prosensa to formulate and perform the aseptic fill of the product for use in a human trial (4/17) |
Transgenomic |
Spectrumedix LLC* |
Agreement under which Transgenomic will provide instrument service and consumables support in the U.S. and other areas for Spectrumedix products |
Spectrumedix has ceased operations; Transgenomic has acquired certain assets and a license from Spectrumedix to manufacture consumables for the systems (4/12) |
Viragen |
Swedish Orphan International AB* (Sweden) |
Licensing agreement for exclusive marketing rights to Multiferon for the European Union; it is approved in Sweden for malignant melanoma and other diseases |
Viragen received about $2M up front and will serve as sole manufacturer for the product; Swedish Orphan will pay for Multiferon at an agreed-upon sales price, and Viragen will receive double-digit royalties on net sales (4/18) |
| Notes: | |||
| * Private companies are indicated with an asterisk. ** Denotes the date the item ran in BioWorld International. | |||
| # Item occurred before the time frame of this chart but was not included in the previous chart. | |||
| Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
| AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; FSE = Franfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets. | |||
